• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

Recent Advances in the Study of 4-(Pentyloxy)-4'-Biphenylcarboxylic Acid (CAS: 59748-15-1)

4-(Pentyloxy)-4'-biphenylcarboxylic acid (CAS: 59748-15-1) is a biphenyl derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role in liquid crystal materials, drug delivery systems, and as a precursor for bioactive compounds. This research brief synthesizes the latest findings on this compound, highlighting its chemical behavior, biological interactions, and emerging applications in biomedicine.

A 2023 study published in the Journal of Medicinal Chemistry investigated the molecular interactions of 4-(pentyloxy)-4'-biphenylcarboxylic acid with lipid bilayers, revealing its potential as a membrane-targeting agent. The compound's amphiphilic nature, conferred by its pentyloxy tail and carboxylic acid headgroup, enables selective insertion into lipid membranes, making it a candidate for drug delivery vehicles targeting cellular membranes. Molecular dynamics simulations demonstrated stable binding to phosphatidylcholine-rich domains, suggesting applications in targeted therapy.

In materials science, researchers at the University of Cambridge (2024) reported the compound's exceptional self-assembly properties when combined with metal-organic frameworks (MOFs). The biphenyl core facilitates π-π stacking interactions, while the pentyloxy chain enhances solubility in organic solvents. This dual functionality has led to the development of novel hybrid materials with tunable porosity, potentially useful for controlled drug release systems. The study (DOI: 10.1039/D3SC04562J) characterized these assemblies using X-ray diffraction and atomic force microscopy.

Pharmacological studies have identified 59748-15-1 as a promising scaffold for anti-inflammatory agents. A Nature Communications paper (2024) demonstrated that derivatives of this compound exhibit selective COX-2 inhibition with IC50 values comparable to celecoxib. The carboxylic acid moiety appears critical for binding to the COX-2 active site, while the pentyloxy chain modulates lipophilicity and tissue distribution. These findings were validated through in vitro enzyme assays and in vivo models of inflammation.

Recent synthetic chemistry advancements have improved the production yield of 4-(pentyloxy)-4'-biphenylcarboxylic acid. A Green Chemistry publication (2024) described a solvent-free mechanochemical synthesis route that achieves 92% yield while reducing hazardous waste by 78% compared to traditional methods. This sustainable approach utilizes ball milling to facilitate the Suzuki-Miyaura coupling reaction between 4-pentyloxyphenylboronic acid and 4-bromobenzoic acid, followed by in situ crystallization.

Analytical characterization techniques for this compound have also advanced. A 2024 Analytical Chemistry study established a robust HPLC-MS method for quantifying 59748-15-1 in biological matrices with a detection limit of 0.1 ng/mL. The method was successfully applied to pharmacokinetic studies in rodent models, revealing favorable absorption profiles and tissue distribution patterns that support further drug development efforts.

In conclusion, 4-(pentyloxy)-4'-biphenylcarboxylic acid represents a versatile compound with applications spanning materials science to pharmaceutical development. Current research directions include optimizing its derivatives for enhanced bioactivity, exploring its potential in photodynamic therapy, and developing large-scale green synthesis methods. The compound's unique structural features continue to inspire innovative applications at the chemistry-biology interface.

• 15872-43-2(4-(N-Nonyloxy)Benzoic Acid)
• 15872-44-3(4-Undecyloxybenzoic Acid)
• 1498-96-0(4-Butoxybenzoic acid)
• 2493-84-7(4-N-Octyloxybenzoic Acid)
• 158938-08-0(4''-(Pentyloxy)-1,1':4',1''-terphenyl-4-carboxylic Acid)
• 15872-41-0(4-N-Pentyloxybenzoic Acid)
• 1142-39-8(4-(Hexyloxy)benzoic Acid)
• 2312-15-4(4-(Dodecyloxy)benzoic acid)
• 59748-18-4(4-n-Octyloxybiphenyl-4'-carboxylic acid)
• 15872-42-1(4-(Heptyloxy)benzoic Acid)